相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
Angela Marrugal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine
Yu-De Chu et al.
CELL DEATH & DISEASE (2019)
Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry
Angela Marrugal et al.
CELLS (2019)
ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells
Fangqiong Li et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
Anam Akram et al.
CURRENT DRUG METABOLISM (2018)
Dancing with the Diva: Hsp90-Client Interactions
Martina Radli et al.
JOURNAL OF MOLECULAR BIOLOGY (2018)
Established, emerging and elusive molecular targets in the treatment of lung cancer
Jean-Nicolas Gallant et al.
JOURNAL OF PATHOLOGY (2018)
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Enriqueta Felip et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Arginine and the metabolic regulation of nitric oxide synthesis in cancer
Rom Keshet et al.
DISEASE MODELS & MECHANISMS (2018)
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
Alessia Spagnuolo et al.
EXPERT OPINION ON EMERGING DRUGS (2018)
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Abdullah Hoter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Biological therapies in nonsmall cell lung cancer
Jon Zugazagoitia et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Heat shock protein antagonists in early stage clinical trials for NSCLC
Lizza E. L. Hendriks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Ubiquitin conjugating enzyme E2 L3 promoted tumor growth of NSCLC through accelerating p27kip1 ubiquitination and degradation
Xingjie Ma et al.
ONCOTARGET (2017)
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy
Roberto Chalela et al.
JOURNAL OF THORACIC DISEASE (2017)
Evidence of MTCBP-1 Interaction With the Cytoplasmic Domain of MT1-MMP: Implications in the Autophagy Cell Index of High-Grade Glioblastoma
Jonathan Pratt et al.
MOLECULAR CARCINOGENESIS (2016)
The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
Kang-Seo Park et al.
CANCER LETTERS (2016)
Identification and Characterization of Potential Biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma
Chiung-Hung Hsu et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Arginine dependence of tumor cells: targeting a chink in cancer's armor
M. D. Patil et al.
ONCOGENE (2016)
Circular RNA-ITCH Suppresses Lung Cancer Proliferation via Inhibiting the Wnt/beta-Catenin Pathway
Li Wan et al.
BIOMED RESEARCH INTERNATIONAL (2016)
HSP90 as a novel molecular target in non-small-cell lung cancer
Khashayar Esfahani et al.
LUNG CANCER-TARGETS AND THERAPY (2016)
UBE2L3 Polymorphism Amplifies NF-κB Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases
Myles J. Lewis et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2015)
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)aEuro
A. -M. C. Dingemans et al.
ANNALS OF ONCOLOGY (2015)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y. -L. Wu et al.
ANNALS OF ONCOLOGY (2015)
Targeting arginine metabolism pathway to treat arginine-dependent cancers
Fuming Qiu et al.
CANCER LETTERS (2015)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein et al.
CANCER RESEARCH (2015)
Maximizing the Therapeutic Potential of HSP90 Inhibitors
Lisa M. Butler et al.
MOLECULAR CANCER RESEARCH (2015)
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis
Shiran Rabinovich et al.
NATURE (2015)
Human nucleolar protein Nop52 (RRP1/NNP-1) is involved in site 2 cleavage in internal transcribed spacer 1 of pre-rRNAs at early stages of ribosome biogenesis
Harunori Yoshikawa et al.
NUCLEIC ACIDS RESEARCH (2015)
Fibulin-5 inhibits Wnt/β-catenin signaling in lung cancer
Xiaojun Chen et al.
ONCOTARGET (2015)
The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells
Hirokazu Hirakawa et al.
CANCER MEDICINE (2015)
Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics
Benjamin Bonavida et al.
REDOX BIOLOGY (2015)
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
Shoucheng Ning et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Heat shock protein 90 inhibitors in non-small-cell lung cancer
Rathi N. Pillai et al.
CURRENT OPINION IN ONCOLOGY (2014)
Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC
Aswin Somasundaram et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
UbcH7 regulates 53BP1 stability and DSB repair
Xiangzi Han et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
Mark W. Richards et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
Mark A. Socinski et al.
CLINICAL CANCER RESEARCH (2013)
Effects of Nitric Oxide on Cell Proliferation Novel Insights
Claudio Napoli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Inhibition of HSP90 molecular chaperones: moving into the clinic
Rocio Garcia-Carbonero et al.
LANCET ONCOLOGY (2013)
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
Balazs Gyorffy et al.
PLOS ONE (2013)
Comprehensive identification of mutational cancer driver genes across 12 tumor types
David Tamborero et al.
SCIENTIFIC REPORTS (2013)
Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges
Melissa M. Phillips et al.
CANCER RESEARCH AND TREATMENT (2013)
Molecular Biology of Lung Cancer-A Review
Dinesh Pendharkar et al.
INDIAN JOURNAL OF SURGICAL ONCOLOGY (2013)
The E3 Ubiquitin Ligase ITCH Negatively Regulates Canonical Wnt Signaling by Targeting Dishevelled Protein
Wei Wei et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Splicing Factor 2-Associated Protein p32 Participates in Ribosome Biogenesis by Regulating the Binding of Nop52 and Fibrillarin to Preribosome Particles
Harunori Yoshikawa et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
E. Normant et al.
ONCOGENE (2011)
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
Barbara Delage et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors
Suiquan Wang et al.
CELL CYCLE (2009)
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase
Elana S. Ehrlich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Molecular origins of cancer: Lung cancer
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target
Marielle I. Gallegos Ruiz et al.
PLOS ONE (2008)
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
W. Xu et al.
BRITISH JOURNAL OF CANCER (2007)
Expression and function of the human androgen-responsive gene ADI1 in prostate cancer
Shane W. Oram et al.
NEOPLASIA (2007)
Projections of global mortality and burden of disease from 2002 to 2030
Colin D. Mathers et al.
PLOS MEDICINE (2006)
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
M Senju et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
SD Dias et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
T Shimamura et al.
CANCER RESEARCH (2005)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2 Neu
WP Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)